The treatment guidelines for non-muscle-invasive bladder cancer (NMIBC) consist of endoscopic resection of the tumor, then administration of drugs into the bladder (intravesical therapy), typically ...

The FDA is currently evaluating the application of intravesical mitomycin for low-grade intermediate-risk non–muscle-invasive bladder cancer.

About UGN-102 UGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently under regulatory review for approval in the treatment of LG-IR-NMIBC.

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

UK-based biopharmaceutical company Prokarium has received two Notices of Allowance from the US Patent and Trademark Office.

Patients were further queried to identify those who received adequate BCG induction (defined as ≥ 5 weekly instillations). They then summarized the distribution of this group and the treatments ...